Gastrointestinal Cancer

Pashtoon M. Kasi, MD, MBBS, MS, assistant professor of oncology and senior associate consultant in the Division of Hematology/Oncology at Mayo Clinic, discusses the application of pharmacogenomics in colorectal cancer (CRC).

Rachna T. Shroff, MD, MS, highlighted the ongoing research efforts in biliary tract cancers, specifically with cholangiocarcinoma treatment.

Because specific risk-reducing interventions may be available, it is important to identify individuals with germline variants in cancer susceptibility genes.

John Strickler, MD, discusses how liquid biopsies are being used to help guide treatment decisions for patients with GI cancers and shed light on other research efforts that are being made to improve outcomes.

Vincent Chung, MD, discusses the therapeutic landscape of early-stage and advanced pancreatic cancer.

Pashtoon M. Kasi, MD, MBBS, MS, provides an overview of the potential for liquid biopsies in CRC and advances being made in the treatment landscape.

Daneng Li, MD, shed light on some of the currently available regimens and ongoing research efforts being conducted in hepatocellular carcinoma and neuroendocrine tumors.

Joseph Chao, MD, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses practice-changing data in metastatic gastroesophageal (GEJ) cancer.

Marwan Fakih, MD, professor, Department of Medical Oncology and Therapeutics Research, associate director for Clinical Investigations, Comprehensive Cancer Center, medical director, Judy and Bernard Briskin Center for Clinical Research, co-director, Gastrointestinal Cancer Program, and section head, Gastrointestinal Medical Oncology, City of Hope, discusses the combination of durvalumab (Imfinzi) and tremelimumab in patients with metastatic colorectal cancer (mCRC).

Vincent Chung, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, Director Phase I Program, City of Hope, discusses sequencing chemotherapy regimens in patients with metastatic pancreatic cancer.

Allyson J. Ocean, MD, discusses the potential impact of SM-88 in the treatment of patients with advanced pancreatic cancer and highlights a platform that patients can use to stay updated on the latest research in the field.

Stephanie K. Dougan, PhD, discusses research aimed at assessing ways of augmenting T-cell immunity in pancreatic cancer.

Vincent J. Picozzi, MD, director, Pancreatic Center of Excellence, Virginia Mason Medical Center, discusses the use of SM-88 in pancreatic cancer.

Michael J. Overman, MD, highlights new combination agents under investigation for the treatment of patients with GI cancers—specifically CRC—and challenges that still need to be addressed.

Amol K. Narang, MD, discusses recent advances made in the treatment of pancreatic cancer and explained how radiation oncology can be used to provide further clinical benefit to this patient population.

Anthony Shields, MD, PhD, oncologist, Department of Oncology, Molecular Imaging and Diagnostics Program, Karmanos Cancer Institute, discusses patient selection criteria for adjuvant therapy in colorectal cancer (CRC).

Pashtoon M. Kasi, MD, MBBS, MS, an assistant professor of Oncology and senior associate consultant in the Division of Hematology/Oncology, Mayo Clinic, discusses the rising incidence of colorectal cancer (CRC).